Patents on glycopeptides of the vancomycin family and their derivatives as antimicrobials: January 1999 – June 2003

Preobrazhenskaya, M. N.; Olsufyeva, Eugenia N.

doi:10.1517/13543776.14.2.141

Cited by 15 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cl N'-amine group of the disaccharide chain of the vancomycin group antibiotics [see below the modifications Ga and Gb, compounds (Ic), (Ie), (If) (IIIi), (IIIk), and (IIIl). Thus, it was shown [15,16] by the example of many derivatives of glycopeptide antibiotics that the introduction of hydrophobic n-alkyl, p-substituted benzyl, or other substituents of related types at various positions of molecule (not only at COOH group or N'-amino group of the disaccharide residue at AR4) imparts the antibiotic of the activity toward GRE [2,15,16]. It has earlier been presumed that a hydrophobic fragment should be attached to 3'-amino group of the disaccharide fragment of vancomycin, eremomycin, or chloroeremomycin, which is similar to the N-replacement by a fatty acid of the aminosugar at AR4 in natural teicoplanin (II).…”

Section: Mementioning

confidence: 99%

“…In the past decade, the frequency of the bacterial infections caused by the strains of microorganisms resistant to all known β -lactam antibiotics, and also to macrolides, aminoglycosides, tetracyclines, and to other antibacterial preparations has sharply grown. 2 The world returns to the situation, which existed before the era of antibiotics when no means for the treatment of heavy bacterial infections exist. Until recently, the glycopeptide vancomycin ( I ) remained the only antibiotic effective at infections caused by multiresistant Gram-positive bacteria; teicoplanin ( II ) was also used on a limited extent.…”

Section: Introductionmentioning

confidence: 99%

“…Now the situation has even more worsened, and practically, there are no drugs for the treatment of such patients. The search for new preparations of group of polycyclic glycopeptides active toward the multidrugresistant bacteria is now carrying out in the leading pharmaceutical companies and laboratories of the world [2]. Eremomycin ( III ), discovered in GINA (Russia) in 1987, belongs to the group of vancomycin antibiotics.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics

Olsuf'eva

Preobrazhenskaya

2006

Russ J Bioorg Chem

View full text Add to dashboard Cite

The main achievements in the development of methods for the design of semisynthetic antibiotics of a new generation belonging to the group of polycyclic glycopeptides directed against infections caused by multidrug-resistant bacteria and dangerous human and animal viruses are reviewed. The review is focused on the results obtained at the Gauze Institute in the area of chemical modification of natural antibiotics (eremomycin, vancomycin, teicoplanin, etc.) directed toward modification of their antibacterial and/or antiviral activity. A special emphasis is placed on the study of the mechanisms of action of these antibiotics, which could be the basis of a rational approach to their chemical modification involving the transformation of the inner binding pocket and the peripheral regions of the molecules that participate in the formation of their complexes with targets. The recently discovered antiviral activity of modified glycopeptides antibiotics is also discussed. A possibility of obtaining new highly active anti-HIV-1 and anti-HIV-2 preparations on the basis of hydrophobic derivatives of the aglycones of glycopeptide antibiotics was demonstrated. New semisynthetic derivatives of antibiotics that exhibit a high antibacterial activity in vivo, have good pharmacological characteristics, and are promising for practical use are described.

show abstract

Section: Mementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics

Olsuf'eva

Preobrazhenskaya

2006

Russ J Bioorg Chem

View full text Add to dashboard Cite

show abstract

“…The emergence of vancomycin‐resistant enterococci and staphylococci422 has encouraged the search for new (lipo)glycopeptides with improved pharmacokinetic and pharmacodynamic properties and activities towards resistant strains 414. 423, 424…”

Section: Glycopeptide Antibioticsmentioning

confidence: 99%

Oligothiophene Isothiocyanates as Fluorescent Markers

Barbarella

2002

Chem. Eur. J.

View full text Add to dashboard Cite

To create a drug, nature's blueprints often have to be improved through semisynthesis or total synthesis (chemical postevolution). Selected contributions from industrial and academic groups highlight the arduous but rewarding path from natural products to drugs. Principle modification types for natural products are discussed herein, such as decoration, substitution, and degradation. The biological, chemical, and socioeconomic environments of antibacterial research are dealt with in context. Natural products, many from soil organisms, have provided the majority of lead structures for marketed anti‐infectives. Surprisingly, numerous “old” classes of antibacterial natural products have never been intensively explored by medicinal chemists. Nevertheless, research on antibacterial natural products is flagging. Apparently, the “old fashioned” natural products no longer fit into modern drug discovery. The handling of natural products is cumbersome, requiring nonstandardized workflows and extended timelines. Revisiting natural products with modern chemistry and target‐finding tools from biology (reversed genomics) is one option for their revival.

show abstract

“…Antiviral activity by entry inhibition was also evaluated by employing antibacterial chemotherapeutics. Vancomycin, eremomycin, and teicoplanin glycopeptide compounds used to treat infections caused by Gram-positive bacteria (Preobrazhenskaya and Olsufyeva, 2004), as well as hydrophobic derivatives of these drugs, were described to possess antiviral activity against HIV (Printsevskaya et al, 2005). A study showed that vancomycin, eremomycin, and teicoplanin were not toxic to Vero and T lymphoblast (CEM) cells.…”

Section: Inhibitors Of Cov Entry Into Host Cellsmentioning

confidence: 99%

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

et al. 2020

View full text Add to dashboard Cite

Coronaviruses (CoVs) are a group of viruses from the family Coronaviridae that can infect humans and animals, causing mild to severe diseases. The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging the development of new therapeutic strategies. Here we present a selection of relevant compounds that have been described from 2005 until now as having in vitro and/or in vivo antiviral activities against human and/or animal CoVs. We also present compounds that have reached clinical trials as well as further discussing the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.

show abstract

Patents on glycopeptides of the vancomycin family and their derivatives as antimicrobials: January 1999 – June 2003

Cited by 15 publications

References 47 publications

Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics

Structure-activity relationships in a series of semisynthetic polycyclic glycopeptide antibiotics

Oligothiophene Isothiocyanates as Fluorescent Markers

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?

Contact Info

Product

Resources

About